title: The V-region repertoire of Haemophilus influenzae type b polysaccharide antibodies induced by immunization of infants.
abstract: Haemophilus influenzae type b (Hib) is a significant pathogen for young children, and three Hib vaccines (named PRP-OMPC, HbOC, and PRP-T) are currently available for young children. Extensive studies of anti-Hib polysaccharide (PS) antibodies (Abs) have shown that the V regions of Abs against the Hib PS comprise a VH gene in the VH3 gene family and a VL gene from various K kappa and V lambda subgroups. To study immunogenic properties of the three vaccines in young children, we determined the VL subgroups and avidities of anti-Hib-PS Abs induced by the three clinically available conjugate vaccines. Ab avidity was measured by determining the concentration of a Hib-PS oligomer that abrogates half of the binding of immunoglobulin G anti-Hib-PS Abs to microwells. The PRP-OMPC vaccine induced lower-avidity Abs than the prelicensure HbOC vaccine (P = 0.05). When we compared anti-Hib-PS Abs expressing V kappa Ia, V kappa II, and V lambda subgroups, a greater Ab response was induced by the prelicensure HbOC vaccine than other vaccines (P < 0.05). When anti-Hib-PS Abs with the V kappa III subgroup were compared, however, both PRP-T and prelicensure HbOC vaccines induced a comparable response, which in turn was greater than those induced by the PRP-OMPC or the postlicensure HbOC vaccine (P < 0.001). The VL repertoire of Abs induced with the prelicensure HbOC or PRP-T vaccine in young children is dominated (about 80%) by anti-Hib-PS Abs using subgroup V kappa II. However, anti-Hib-PS using V kappa II VL accounts for only about 40% of the total anti-Hib-PS Abs induced with the PRP-OMPC vaccine or the postlicensure HbOC. Our data suggest that immunogenic properties of Hib vaccines in young children vary depending on the vaccine preparations as well as the vaccine types.
authors.affiliation: Department of Pathology and Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
authors.forename: G H
authors.initials: GH
authors.lastname: Chung
authors.forename: K H
authors.initials: KH
authors.lastname: Kim
authors.forename: R S
authors.initials: RS
authors.lastname: Daum
authors.forename: R A
authors.initials: RA
authors.lastname: Insel
authors.forename: G R
authors.initials: GR
authors.lastname: Siber
authors.forename: S
authors.initials: S
authors.lastname: Sood
authors.forename: R K
authors.initials: RK
authors.lastname: Gupta
authors.forename: C
authors.initials: C
authors.lastname: Marchant
authors.forename: M H
authors.initials: MH
authors.lastname: Nahm
mesh_terms: D000907:Antibodies, Bacterial / Q000276:immunology*; D000915:Antibody Affinity; D000916:Antibody Diversity; D018073:Haemophilus Vaccines / Q000276:immunology*; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007145:Immunoglobulin kappa-Chains / Q000276:immunology; D007146:Immunoglobulin lambda-Chains / Q000276:immunology; D007223:Infant; D018074:Vaccines, Conjugate
chemical_list: D000907:Antibodies, Bacterial; D018073:Haemophilus Vaccines; D007074:Immunoglobulin G; D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D018074:Vaccines, Conjugate